Skip to main content

Drug Interactions between Mifeprex and Prepidil

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

dinoprostone topical miFEPRIStone

Applies to: Prepidil (dinoprostone topical) and Mifeprex (mifepristone)

ADJUST DOSING INTERVAL: The use of oxytocic agents in combination with each other may result in additive pharmacodynamic effects, including stimulation of uterine hypertonus, which can lead to uterine rupture or cervical laceration, particularly in the presence of an undilated or poorly dilated cervix.

MANAGEMENT: Some authorities consider the concomitant use of dinoprostone with other oxytocic agents to be contraindicated. Concomitant use of dinoprost or carboprost with other oxytocic agents is generally not recommended. If necessary, administration of other oxytocic agent(s) should not be started until at least 6 to 12 hours after the insertion of dinoprostone vaginal gel, or at least 30 minutes after the removal of the dinoprostone vaginal insert. Recommended time intervals vary by brand and manufacturer. It is recommended to refer to local guidelines or drug product labeling.

References

  1. "Product Information. Prostin E2 (dinoprostone topical)." Apothecon Inc (2022):
  2. "Product Information. Prostin E2 (dinoprostone topical)." Pharmacia and Upjohn (2002):
  3. "Product Information. Prostin F2A (dinoprost)." Pharmacia Canada Inc (2002):
  4. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  5. Cerner Multum, Inc. "Australian Product Information." O 0
  6. "Product Information. Carboprost (Reach) (carboprost)." Reach Pharmaceuticals Pty Ltd 08 (2023):
View all 6 references

Switch to consumer interaction data

Drug and food interactions

Moderate

miFEPRIStone food

Applies to: Mifeprex (mifepristone)

ADJUST DOSING INTERVAL: Food may significantly increase the plasma concentrations of mifepristone.

GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of mifepristone. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Because pharmacokinetic interactions involving grapefruit juice are often subject to a high degree of interpatient variability, the extent to which a given patient may be affected is difficult to predict.

MANAGEMENT: When mifepristone is used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome, it should be taken with food to achieve consistent plasma drug levels. Patients should be advised to avoid consuming grapefruit or grapefruit juice during treatment with mifepristone, as it may cause increased adverse effects such as headache, dizziness, fatigue, nausea, vomiting, cramping, diarrhea, hypokalemia, adrenal insufficiency, vaginal bleeding, arthralgia, peripheral edema, and hypertension. Because mifepristone is eliminated slowly from the body, the interaction with grapefruit juice may be observed for a prolonged period.

References

  1. "Product Information. Mifeprex (mifepristone)." Danco Laboratories PROD (2001):
  2. "Product Information. Korlym (mifepristone)." Corcept Therapeutics Incorporated (2012):

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer